Autoimmune Technologies, LLC

The Administrators of the Tulane Educational Fund

Parion Sciences, Inc.

The Administration of the Tulane Educational Fund

Samuel E Hopkins

Robert F Garry

Russell B Wilson

Bruce Alan Bunnell

Luis Manuel Branco

Michael Ross Johnson

Luis M Branco

Bruce A Bunnell

Immunoprotective primary mesenchymal stems cells (IP-MSC) which episomally express immunoreactive polypeptides that specifically target a pathogen (e.g., an infectious species of virus, bacterium, or parasite) or toxin are described herein. The immunoreactive polypeptides can be, e.g., full antibodies, single-chain antibodies (ScFV), Fab or F(ab)antibody fragments, diabodies, tribodies, and the like). Optionally IP-MSC are transfected to express one or more other immunomodulating polypeptides, e.g., a cytokine such as an interleukin (e.g., IL-2, IL-4, IL-6, IL-7, IL-9, and IL-12), an interferon (e.g., IFN&#x3b1;, IFN&#x3b2;, or IFN&#x3c9;), and the like, which can enhance the effectiveness of the immunoreactive polypeptides.

Immunoprotective primary mesenchymal stem cells and methods

Immunoprotective primary mesenchymal stems cells (IP-MSC) which episomally express multiple immunoreactive polypeptides that specifically target a pathogen (e.g., an infectious species of virus, bacterium, or parasite) or toxin are described herein. The IP-MSC express two or more (e.g., 2 to about 100) immunoreactive polypeptides (e.g., full antibodies, single-chain antibodies (ScFV), Fab or F(ab)antibody fragments, diabodies, tribodies, and the like), and optionally one or more other immunomodulating polypeptides, e.g., a cytokine such as an interleukin (e.g., IL-2, IL-4, IL-6, IL-7, IL-9, and IL-12), an interferon (e.g., IFN&#x3b1;, IFN&#x3b2;, or IFN&#x3c9;), and the like, which can enhance the effectiveness of the immunoreactive polypeptides.

Prophylactic treatment methods are provided for protection of individuals and/or populations against infection from airborne pathogens. In particular, prophylactic treatment methods are provided including administering a sodium channel blocker or pharmaceutically acceptable salts thereof to one or more members of a population at risk of exposure to or already exposed to one or more airborne pathogens, either from natural sources or from intentional release of pathogens into the environment.

Methods of reducing risk of infection from pathogens

Growing community of inventors

Raleigh, NC, United States of America

Samuel E Hopkins